BioRevolution Featured in BioCentury for Innovative Approach to Muscle Health and Glycogen Biology
Redwood City, CA, February. 18, 2026 – BioRevolution, a next-generation biotech company dedicated to building, restoring, and preserving muscle mass and strength for Longevity, today was featured in an Emerging Company Profile by BioCentury, a leading life sciences publication covering strategic issues and emerging trends in biotech and pharmaceuticals.
In the article titled “BioRevolution: Tapping glycogen reserves to build muscle,” BioCentury highlights our first‑in‑class small molecule program, BREV-100, and its mechanism of breaking down glycogen to potentially drive meaningful gains in muscle strength and function for patients. We aim to advance BREV-100 into IND enabling studies and conduct additional in vivo efficacy studies in Glycogen Storage Disorders, Muscular Dystrophies, Obesity, and Sarcopenia.
“Being featured in BioCentury underscores the importance of building muscle mass and strength as the next frontier in extending healthy longevity. Muscle loss is central to numerous diseases and aging, and we’re grateful for the opportunity to share our vision for harnessing glycogen biology to potentially create functional benefit for patients.” said Thomas Butler, Co‑Founder and CEO of BioRevolution.
The BioCentury profile also highlights BioRevolution’s scientific rationale and broader vision for expanding its platform into multiple muscle‑wasting diseases, emphasizing the potential impact on Longevity and patient quality of life.
Read the full article here: https://www.biocentury.com/article/658336.
About BioRevolution
BioRevolution is a biopharmaceutical company dedicated to building, restoring, and preserving muscle mass and strength for Longevity. Our approach harnesses the body’s natural, evolutionary mechanism of building functional muscle with broad applicability across multiple muscle wasting diseases, including Glycogen Storage Disorders, Muscular Dystrophies, Obesity, and Sarcopenia.
The company’s lead program, BREV-100, is a first-in-class, oral small molecule that targets the glycogen degradation pathway to activate the body’s central mechanism of building functional skeletal muscle starting with Pompe disease, where excess glycogen drives progressive muscle impairment.
BioRevolution is led by a seasoned team that has advanced multiple innovative therapies into the clinic and is united by a mission to transform muscle biology and extend healthy human lifespan for millions of patients living with rare and chronic diseases.
Company Contact:
info@biorevolutiontx.com
